HeartBeam (NASDAQ:BEAT) Cut to Neutral at HC Wainwright

HC Wainwright lowered shares of HeartBeam (NASDAQ:BEAT) from a buy rating to a neutral rating in a report published on Tuesday, Marketbeat Ratings reports. HC Wainwright also issued estimates for HeartBeam’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.24) EPS.

A number of other research firms also recently issued reports on BEAT. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartBeam in a research report on Thursday, July 2nd. Maxim Group assumed coverage on HeartBeam in a report on Tuesday, July 14th. They issued a “buy” rating and a $2.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

HeartBeam Stock Performance

Shares of NASDAQ BEAT opened at $0.38 on Tuesday. The business’s 50 day moving average price is $0.48 and its 200-day moving average price is $0.77. HeartBeam has a fifty-two week low of $0.36 and a fifty-two week high of $4.00. The company has a market cap of $21.36 million, a price-to-earnings ratio of -0.74 and a beta of -0.80.

HeartBeam (NASDAQ:BEAT) last posted its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Sell-side analysts predict that HeartBeam will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On HeartBeam

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of HeartBeam in the 2nd quarter worth $741,000. Sigma Planning Corp grew its stake in HeartBeam by 86.9% during the 2nd quarter. Sigma Planning Corp now owns 247,700 shares of the medical research company’s stock worth $186,000 after buying an additional 115,150 shares during the last quarter. Finally, Beacon Pointe Advisors LLC acquired a new position in HeartBeam during the 2nd quarter valued at about $185,000. 7.77% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about HeartBeam

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.37 from a loss of $0.41 and increased its FY2027 estimate to a loss of $0.24 from a loss of $0.31. The firm also improved estimates for several upcoming quarters, suggesting expectations for narrower losses and potentially better operating performance.
• Positive Sentiment: Reported short interest was zero shares as of September 24, producing a short-interest ratio of 0.0 days. This indicates that short sellers are not currently creating a significant source of selling pressure, although the reported figure may warrant verification given the article’s conflicting description of a “large increase” in short interest.
• Neutral Sentiment: Despite the improved earnings forecasts, HC Wainwright kept its Neutral rating on HeartBeam. The revised projections still imply ongoing losses, including expected EPS of negative $0.09 for Q3 2026 and negative $0.08 for Q4 2026.
• Negative Sentiment: HC Wainwright lowered its rating on HeartBeam, signaling reduced conviction in the stock’s near-term upside. HeartBeam Stock Rating Lowered by HC Wainwright
• Negative Sentiment: HeartBeam is shifting its focus toward technology designed to detect heart attacks. While the strategy could support future commercialization, it also highlights that the company remains in an early-stage development phase and has yet to establish consistent profitability. HeartBeam Shifts Focus to Heart-Attack Detection Technology

About HeartBeam

HeartBeam, Inc develops wearable and digital cardiac-monitoring technologies designed to help detect and evaluate heart conditions outside traditional clinical settings. The company’s platform is intended to capture electrocardiogram (ECG) data in a portable, cable-free format and transmit that information through a connected mobile device.

HeartBeam’s technology is based on three-dimensional vector ECG recordings, which are designed to provide electrical views of the heart from multiple directions rather than relying solely on a conventional single-lead wearable reading.